logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5148.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5148.produseast1
Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs | Journal Article / Short Report | MSF Science Portal
Journal Article
|Short Report

Pregnancy and birth outcomes in patients with multidrug-resistant tuberculosis treated with regimens that include new and repurposed drugs

Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed SM, Algozhin Y, Coutisson S, Garavito ES, Hewison CCH, Holtzman D, Huerga H, Janmohamed A, Khan PY, Jacques GL, Lomtadze N, Melikyan N, Mitnick CD, Mussabekova G, Osso E, Perea S, Putri FA, Rashidov M, Rich ML, Sakhabutdinova Y, Seung KJ, Stambekova A, Vásquez DV, Franke MF, Khan UT
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.

Subject Area

tuberculosiswomen's healthantimicrobial resistance

Collections

Expanding access to lifesaving new TB toolsThe endTB project

Languages

English
DOI
10.1093/cid/ciad445
Published Date
25 Jan 2024
PubMed ID
37606512
Journal
Clinical Infectious Diseases
Volume | Issue | Pages
Volume 78, Issue 1, Pages 144-148
Dimensions Badge